Novartis AG (NVS) - Analysis

25.25 CAD

0

0%

Last update Dec 1, 11:50 AM EST

Market closed

Day range

25.25

25.25

25.25

Previous close

25.25

Open

25.25

Access this stock data via API

Novartis AG

25.25

0

0%

Analysis

Revenue estimate	Next quarter (Dec 2025)	Current year (Dec 2025)	Next year (Dec 2026)
Number of Analysts	4	14	13
Avg. estimate	13.78B	55.06B	56.55B
Low estimate	13.62B	52.72B	54.19B
High estimate	13.85B	57.96B	60.66B
Last year sales	13.15B	50.32B	55.06B
Sales growth	0.05	0.09	0.03

Access /revenue_estimate data via our API — starting from the Ultra plan.

EPS revisions	Next quarter (Dec 2025)	Current year (Dec 2025)	Next year (Dec 2026)
Up last 7 days	0	0	0
Up last 30 days	0	0	0
Down last 7 days	0	0	0
Down last 30 days	0	0	0

Access /eps_revisions data via our API — starting from the Ultra plan.

Analyst ratings

Firm	Date	Action
Jefferies	Oct 27, 2025	Assumes
UBS	Feb 13, 2025	Downgrade
Erste Group	Nov 19, 2024	Downgrade
Jefferies	Sep 03, 2024	Downgrade
Morgan Stanley	Sep 25, 2023	Upgrade
Wolfe Research	May 09, 2022	Downgrade
Exane BNP Paribas	Dec 06, 2021	Downgrade
Bryan Garnier	Dec 03, 2021	Downgrade
Deutsche Bank	Sep 20, 2021	Downgrade
Argus Research	Mar 10, 2021	Downgrade
Deutsche Bank	Jan 15, 2021	Initiates
Morgan Stanley	Sep 01, 2020	Upgrade
Guggenheim	Feb 25, 2020	Downgrade
Guggenheim	Apr 25, 2019	Upgrade
Morgan Stanley	Apr 10, 2019	Downgrade
Goldman Sachs	Nov 19, 2018	Upgrade
Citigroup	Sep 11, 2018	Upgrade
Barclays	Jul 19, 2018	Upgrade
HSBC	May 29, 2018	Downgrade
Credit Suisse	May 25, 2018	Upgrade
Barclays	Oct 25, 2017	Downgrade
Morgan Stanley	Jul 26, 2017	Upgrade
Credit Suisse	Jul 05, 2017	Downgrade
Credit Suisse	Jan 11, 2017	Downgrade
JP Morgan	Jan 03, 2017	Downgrade
Argus Research	Nov 10, 2016	Upgrade
Morgan Stanley	Apr 12, 2016	Downgrade
Argus Research	Apr 05, 2016	Initiates
UBS	Apr 01, 2016	Downgrade
Citigroup	Mar 29, 2016	Downgrade

Access /analyst_ratings/light data via our API — starting from the Ultra plan.